Elevance Health Q2 EPS Estimate Decreased by Zacks Research

Elevance Health, Inc. (NYSE:ELV) – Equities researchers at Zacks Research lowered their Q2 2025 earnings per share estimates for shares of Elevance Health in a research report issued on Thursday, January 30th. Zacks Research analyst K. Dey now anticipates that the company will post earnings per share of $9.85 for the quarter, down from their prior estimate of $10.35. The consensus estimate for Elevance Health’s current full-year earnings is $34.09 per share. Zacks Research also issued estimates for Elevance Health’s Q4 2025 earnings at $5.31 EPS, FY2025 earnings at $34.16 EPS, Q1 2026 earnings at $12.30 EPS, Q2 2026 earnings at $11.67 EPS, Q3 2026 earnings at $10.23 EPS, Q4 2026 earnings at $6.10 EPS and FY2026 earnings at $40.30 EPS.

Elevance Health (NYSE:ELV) last issued its earnings results on Thursday, January 23rd. The company reported $3.84 EPS for the quarter, topping the consensus estimate of $3.80 by $0.04. Elevance Health had a return on equity of 18.28% and a net margin of 3.38%.

A number of other brokerages have also recently commented on ELV. Stephens cut shares of Elevance Health from an “overweight” rating to an “equal weight” rating and cut their price target for the stock from $520.00 to $440.00 in a research note on Wednesday, January 22nd. Truist Financial decreased their price target on Elevance Health from $520.00 to $480.00 and set a “buy” rating on the stock in a research note on Monday, January 6th. Morgan Stanley dropped their price objective on Elevance Health from $643.00 to $551.00 and set an “overweight” rating for the company in a research note on Wednesday, October 23rd. Argus restated a “hold” rating and issued a $405.40 target price on shares of Elevance Health in a research note on Wednesday, January 29th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $485.00 target price on shares of Elevance Health in a research report on Friday, January 24th. Four research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $517.03.

Elevance Health Price Performance

NYSE:ELV opened at $395.82 on Monday. The company has a market capitalization of $91.80 billion, a price-to-earnings ratio of 15.46, a PEG ratio of 1.20 and a beta of 0.84. The company has a 50-day moving average of $386.50 and a 200-day moving average of $457.14. Elevance Health has a 52 week low of $362.21 and a 52 week high of $567.26. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.50 and a current ratio of 1.45.

Institutional Investors Weigh In On Elevance Health

Institutional investors and hedge funds have recently made changes to their positions in the company. Centaurus Financial Inc. lifted its position in Elevance Health by 66.9% during the 2nd quarter. Centaurus Financial Inc. now owns 918 shares of the company’s stock valued at $498,000 after purchasing an additional 368 shares during the period. Czech National Bank raised its stake in shares of Elevance Health by 6.7% during the third quarter. Czech National Bank now owns 47,237 shares of the company’s stock worth $24,563,000 after buying an additional 2,947 shares during the last quarter. Handelsbanken Fonder AB lifted its holdings in Elevance Health by 4.1% in the third quarter. Handelsbanken Fonder AB now owns 75,320 shares of the company’s stock valued at $39,166,000 after buying an additional 2,987 shares during the period. GAMMA Investing LLC lifted its holdings in Elevance Health by 19.3% in the third quarter. GAMMA Investing LLC now owns 3,098 shares of the company’s stock valued at $1,611,000 after buying an additional 502 shares during the period. Finally, Chemistry Wealth Management LLC boosted its stake in Elevance Health by 4.0% in the third quarter. Chemistry Wealth Management LLC now owns 6,793 shares of the company’s stock valued at $3,533,000 after acquiring an additional 261 shares during the last quarter. Institutional investors own 89.24% of the company’s stock.

Elevance Health Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 25th. Stockholders of record on Monday, March 10th will be paid a $1.71 dividend. This is a boost from Elevance Health’s previous quarterly dividend of $1.63. This represents a $6.84 annualized dividend and a dividend yield of 1.73%. The ex-dividend date of this dividend is Monday, March 10th. Elevance Health’s dividend payout ratio (DPR) is 26.71%.

About Elevance Health

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.